Related Experiment Video
Updated: Apr 18, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
[Therapy-resistant hypertension].
1Medizinische Klinik, St.-Josefs-Hospital Cloppenburg, Krankenhausstr. 13, 49661, Cloppenburg, Deutschland, joachim.schrader@kk-om.de.
Therapy-resistant hypertension affects 10-20% of patients, requiring intensive strategies for blood pressure control. Accurate diagnosis, excluding pseudoresistance, is crucial for effective management and improved cardiovascular outcomes.
Area of Science:
- Cardiology
- Nephrology
- Internal Medicine
Context:
- Therapy-resistant hypertension (TRH) is a prevalent clinical challenge, affecting 10-20% of patients.
- TRH is defined as uncontrolled hypertension despite at least three antihypertensive agents from different classes, including a diuretic.
- Poor prognosis associated with TRH necessitates aggressive management strategies.
Purpose:
- To emphasize the critical importance of accurate diagnosis in TRH management.
- To outline diagnostic steps including the exclusion of pseudoresistance, secondary causes, and sleep apnea.
- To detail therapeutic options for TRH, ranging from optimized pharmacotherapy to invasive procedures.
Summary:
- Accurate diagnosis is paramount, requiring exclusion of pseudoresistance (e.g., incorrect BP measurement, non-compliance, drug interactions) and secondary causes.
- 24-hour ambulatory blood pressure monitoring is essential to confirm true resistant hypertension.
- Optimizing pharmacotherapy with multiple agents is key, prioritizing patient compliance by minimizing side effects. Invasive options like renal denervation are reserved for refractory cases.
Impact:
- Improved diagnostic accuracy can significantly reduce the number of patients misdiagnosed with TRH.
- Comprehensive therapeutic strategies, including optimized medication regimens and addressing lifestyle factors, can lead to better blood pressure control.
- Successful management of TRH improves cardiovascular prognosis and patient outcomes, underscoring the need for intensive, patient-centered care.
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Hypertension I: Introduction
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension V: Nursing Management
Hypertension II: Pathophysiology

